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Synthesis and SAR assessment of novel Tubathian
analogs in the pursuit of potent and selective
HDAC6 inhibitors†
Rob De Vreese,a Yves Depetter,a Tom Verhaeghe,b Tom Desmet,b Veronick Benoy,c
Wanda Haeck,c Ludo Van Den Boschc and Matthias D’hooghe*a
The synthesis of novel isoform-selective HDAC inhibitors is considered to be an important, emerging ﬁeld
in medicinal chemistry. In this paper, the preparation and assessment of thirteen selective HDAC6 inhibi-
tors is disclosed, elaborating on a previously developed thiaheterocyclic Tubathian series. All compounds
were evaluated in vitro for their ability to inhibit HDAC6, and a selection of ﬁve potent compounds was
further screened toward all HDAC isoforms (HDAC1-11). The capability of these Tubathian analogs to
inhibit α-tubulin deacetylation was assessed as well, and ADME/Tox data were collected. This thorough
SAR evaluation revealed that the oxidized, para-substituted hydroxamic acids can be recognized as valu-
able lead structures in the pursuit of novel potent and selective HDAC6 inhibitors.
Introduction
The interplay between histone acetyltransferases (HATs) and
histone deacetylases (HDACs) represents an important epige-
netic regulatory mechanism in the biochemistry of life pro-
cesses.1 This epigenetic interaction controls the structural
transformation of DNA between a compact, inactivated form
and a loosely bound, activated form, and thus plays a major
role in the functioning of cells.2 Besides the regulation of
histone acetylation, HATs and HDACs mediate the acetylation
of other proteins as well, and therefore these enzymes are
more correctly referred to as lysine acetyltransferases (KATs)
and deacetylases (KDACs).3 The KDAC family can be divided
into four classes (I, IIa/IIb, III and IV), existing of 18 proteins.4
Selective inhibition of these isoforms could significantly con-
tribute to our knowledge on this family of epigenetic erasers
(enzymes known to catalyze the removal of epigenetic marks),
and potentially lead to new drugs. One of these proteins,
defined as HDAC6, emerged in recent years as a valuable
target in drug design and belongs to the class IIb HDACs.
Because of its cytoplasmic location, HDAC6 has many inter-
action partners other than histones, and this feature renders it
an interesting protein to study the acetylation status of pro-
teins in cells.3 The use of small molecule inhibitors of
HDAC6 has been proposed as an eﬃcient strategy to block its
catalytic activity, and is therefore considered to be a valuable
new approach in neurodegenerative diseases,5 cancer6 and
immunology research.7
A milestone achievement in the quest for selective HDAC6
inhibitors concerned the development of Tubastatin A (1) in
2010, a molecule with a good ‘drug-likeness’ profile that
showed great promise in vitro and in vivo.8 This discovery,
together with the growing interest of academia and industry in
the design of small molecule inhibitors, prompted us to
pursue new analogs of this lead compound with possibly
enhanced pharmacological properties. Based on available
structure–activity relationships (SAR), sulfur analogs 2 of
Tubastatin A (1) were constructed recently by our group, as
shown in Fig. 1, and tested for their ability to inhibit HDAC6
in vitro.9 Within this thiaheterocyclic series, sulfone derivatives
2c and 2d – designated as Tubathians – exhibited the most
pronounced activity and selectivity toward HDAC6.
The first major objective of the present study comprised a
full and thorough biological evaluation of this Tubathian
family 2 to shed more light on their potential as lead struc-
tures for HDAC6 inhibitor design. Furthermore, in view of the
promising preliminary results of these Tubathian molecules,
an expansion of compound library 2 to general structures 3
was envisioned as a second major objective to study structure–
activity relationships in more detail. Guided by in-house
docking studies and by the advancing progress made in the
literature with regard to selective HDAC6 inhibitor develop-
ment,10 three main structural modifications of template mole-
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cules 2 were proposed. First, modification of the ring size of
the non-aromatic C-ring (a six-membered versus a five-
membered thiaheterocyclic ring) was pursued. A second key
modification of the core scaﬀold molecule comprised assess-
ment of the oxidation state of the sulfur atom, implying the
selective synthesis of sulfides, sulfoxides and sulfones.
Recently, also meta-substituted benzohydroxamic acids have
been studied and showed dual HDAC6/8 selectivity.11 Hence,
the third structural variation involved the synthesis and evalu-
ation of the meta-substituted counterparts of the Tubathian
core structure. Once in hand, this set of compounds 2 and 3
will then be subjected to an elaborate biological investigation
of their medicinal relevance as potential eﬃcient and selective
HDAC6 inhibitors.
Results and discussion
In silico docking studies of the proposed compounds 3 using a
homology model of HDAC6 revealed that all theoretical struc-
tures fit the binding pocket quite well and thus represent com-
pounds worth to be studied (Fig. 2). In general, the sulfone
derivatives proved to have slightly higher predicted binding
energies (better binding) than the corresponding sulfides, due
to additional interactions of the sulfone group with surround-
ing residues. The para-substituted compounds resulted in
better binding energies than the meta-substituted ones, and
phenyl substitution (R = Ph) on the aromatic ring seemed to
be preferred because of π-stacking interactions with the side
chain of a phenylalanine amino acid. However, it must be
emphasized that the diﬀerences in calculated binding energies
of these virtual complexes were small, pointing to the necessity
of lab synthesis and detailed biological evaluation in vitro (for
more details on these docking studies, see ESI†).
The synthesis of compounds 2 has been reported before by
us, and the same approach was used here for the preparation
of molecules 3 (Scheme 1 and Fig. 3).9 First, the tricyclic
indole-containing ‘cap’-group was synthesized via a bismuth-
nitrate catalyzed Fisher-indole synthesis between aromatic
hydrazines 4 and sulfur-containing cyclic ketones 5.12 The
obtained tricycles 6 were modified through selective oxidation
of the sulfur atom employing meta-chloroperbenzoic acid, with
or without the addition of boron trifluoride, leading to the
corresponding sulfoxides 7 and sulfones 8, respectively.
7-Bromo-2,3-dihydrothieno[3,2-b]indole 6f (R = Br, n = 0)
appeared hard to purify because it contained the corres-
ponding sulfoxide as a side product, which could not be
removed by means of column chromatography. Therefore, this
compound was used as an intermediate toward direct sulfoxi-
dation, resulting in the synthesis of sulfoxide 7c (R = Br, n = 0).
Phenyl-containing sulfone 8f (R = Ph, n = 1) was obtained
through full oxidation of sulfide 6c (R = Br, n = 1) to sulfone 8c
(R = Br, n = 1), followed by a Suzuki–Miyaura cross coupling.
The obtained thiaheterocycles 6, 7 and 8 were N-deprotonated
with sodium hydride and the resulting anion subsequently
quenched with methyl 4-(bromomethyl)benzoate or methyl 3-
(bromomethyl)benzoate 9 to give methyl esters 10. In the final
step, esters 10 were converted to hydroxamic acids 3 upon
treatment with a large excess of hydroxyl amine, which were
subsequently used for pharmacological evaluation.
As can be seen from Fig. 3, no five-membered cyclic
thioether-containing hydroxamic acids (with n = 0 and x = 0)
were obtained, which was due to the fact that reaction of com-
pound 6d (R = H, n = 0) with sodium hydride and methyl 3-
Fig. 1 Expanded SAR of sulfur analogs of Tubastatin A (1).
Fig. 2 Docking of selected molecules from class 3 (left: 3a; right: 3l) in
a homology model of HDAC6 (green: carbon, blue: nitrogen, red:
oxygen, yellow: sulfur).
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Scheme 1 Synthesis of the expanded Tubathian library 3. Conditions: a: 1 equiv. ketone 5, 0.2 equiv. Bi(NO3)3·5H2O, MeOH, Δ, 3.5 h (30–90%, 6a–
f ). b: 1 equiv. mCPBA (≤77%), 4 equiv. BF3·O(C2H5)2, THF, −20 °C, N2, 2 h (41–83%, 7a–c). c: 3 equiv. mCPBA (≤77%), THF, 0 °C to rt, 2 h (52–80%,
8a–e). d: 2 equiv. phenylboronic acid, Na2CO3 (7 equiv.), 0.04 equiv. Pd(PPh3)4, toluene/ethanol/H2O (2/1/1), Δ, N2, 8 h (60%, 8f ). e: (1) 1 equiv. NaH,
DMF, rt, N2, 0.5 h (2) 1 equiv. methyl (bromomethyl)benzoate 9, 0.01 equiv. KI, DMF, 80 °C, N2, 2 h (21–80%, 10a–m). f: 100 equiv. NH2OH (50% in
H2O), 50 equiv. KOH (4 M in MeOH), THF, rt or Δ, 10 min (5–70%, 3a–m).
Fig. 3 Overview of the newly synthesized hydroxamic acids 3.
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(bromomethyl)benzoate or methyl 4-(bromomethyl)benzoate
always resulted in complex reaction mixtures. To circumvent
this problem, an alternative approach toward the synthesis of
these molecules was attempted, in which the synthesis of the
‘cap’-group was postponed to a later stage in the reaction
pathway, however without any success.13 In total, a set of thir-
teen novel hydroxamic acids 3a–m was prepared and, together
with the four earlier discovered Tubathian HDAC6 inhibitors
2a–d, evaluated for their ability to selectively inhibit HDAC6.
A preliminary in vitro screening of their inhibitory potential
toward HDAC6 at a concentration of 10 µM learned that the
meta-substituted compounds 3a–h only moderately inhibited
HDAC6 (34–74% inhibition, relative to the control; see ESI† for
data). This stands in sharp contrast to all the para-substituted
compounds 2a–d and 3i–m, as these molecules completely
inhibited HDAC6 at this concentration (99–100% inhibition,
relative to the control; see ESI† for data). It must be noted that
within the meta-substituted series, phenyl-decorated com-
pound 3e showed the highest inhibition percentage (74%), as
predicted by the docking studies. Subsequently, the IC50-
values of the five new para-substituted compounds 3i–m were
determined and compared with the previously obtained results
for compounds 2a–d (Table 1).9 All molecules exhibited low
nanomolar IC50-values toward HDAC6 (≤22 nM), and the
6-membered sulfones 2c, 2d and 3k displayed the highest
HDAC6 inhibitory activity (1.9, 3.7 and 3.4 nM, respectively).
As noted in our previous communication,9 this could be
explained (and confirmed in silico) through hydrogen bond for-
mation of both oxygen atoms on the sulfone moiety with sur-
rounding residues.
The selectivity toward HDAC6 was assessed on the enzy-
matic level through a full-panel HDAC1-11 screening of repre-
sentative compounds 2b, 2c, 2d, 3j and 3l. Compounds 2b, 2d
and 3j were selected to compare the influence of the oxidation
state of sulfur (R2S, R2SO and R2SO2) on the selectivity. The
influence of the ring size (thiolane vs. thiane) on the inhibitory
selectivity was studied by selection of hydroxamic acids 2c and
3l. The data in Table 2 reveal that all screened compounds
display a similar selectivity profile. These molecular entities
inhibit HDAC1, 2, 3, 10 and 11 at IC50-values higher than
5 µM, except for the five-membered sulfone 3j, which also
shows a reasonable aﬃnity for HDAC11 (IC50 = 0.52 µM). All
compounds inhibit HDAC4, 5 and 8 with IC50-values around
1 µM, and HDAC7 and 9 at IC50-values between 0.1 and 1 µM.
In all cases, the lowest values can be observed with respect to
HDAC6 inhibition, with IC50-values <30 nM. After this in-
depth selectivity screening, it can be stated that this set of
Tubathian and related compounds selectively inhibit HDAC6
in a potent and pronounced way, but also display some moder-
ate aﬃnity for class IIa HDACs (HDAC4, 5, 7 and 9) and
HDAC8.
Table 1 In vitro enzyme inhibition data: IC50-values toward HDAC6
Compound 2a 2b 2c 2d 3i 3j 3k 3l 3m
HDAC6 IC50 (nM) 15 22 1.9 3.7 14 9.4 3.4 8.2 16
Table 2 HDAC1-11 screening of selected compounds 2b, 2c, 2d, 3j and 3l (IC50-values in µM)
a,b
Compound HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11
2b 21 NC 23 1.5 1.8 0.0220 0.2 2.8 0.8 21 9.7
2c 11 26 29 1.6 0.5 0.0019 0.1 1.7 0.3 7.7 NC
2d 12 29 26 1.9 0.5 0.0037 0.1 0.9 0.5 5.9 NC
3j 9.4 >30 24 1.2 1.3 0.0094 0.2 2.4 0.5 6.4 0.5
3l 12 >30 NC 0.6 0.4 0.0082 0.1 1.9 0.2 13 17
a Reference compound: Trichostatin A (HDAC6 IC50 = 0.0093 µM).
b Tubastatin A HDAC6 inhibition IC50 = 0.015 µM.
8a. NC: IC50-value not
calculable. Concentration-response curve shows less than 25% eﬀect at the highest validated testing concentration (30 µM). >30: IC50 value above
the highest test concentration. Concentration-response curve shows less than 50% eﬀect at the highest validated testing concentration (30 µM).
Fig. 4 (a and b) Comparison of α-tubulin and histone hyperacetylation of compounds 2a–d, 3i–m and control substance Tubastatin A (Neuro-2a
cells, 1 µM).
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Next, the potency and selectivity of compounds 2a–d, 3i–m
together with control substance Tubastatin A was evaluated on
a cellular level (Neuro-2a cells) by determining their ability to
modify the acetylation level of α-tubulin (a specific HDAC6
substrate) and histones via western blots. First, all the com-
pounds were tested at 1 µM for both assays. From Fig. 4 it can
be seen that the HDAC6 inhibitors clearly hyperacetylate
α-tubulin at this concentration and do not aﬀect the acetyl-
ation status of histones. Second, Tubathians 2a–d and control
molecule Tubastatin A were tested at a range of concentrations
(10, 50, 100, 500 and 1000 nM), revealing that these com-
pounds already presented a maximal acetyl α-tubulin/α-tubulin
ratio at a concentration of 100 nM. Finally, also the newly syn-
thesized Tubathian analogs 3i–m were tested at a lower con-
centration of 10 nM, pointing to the conclusion that
compound 3k (together with control substance Tubastatin A)
demonstrated an even more pronounced activity than the
other compounds (for more details, see ESI†).
With a strong HDAC inhibition profile for this Tubathian
family in hand, the following step involved acquirement of
in vitro ‘ADME’ (absorption, distribution, metabolism, and
excretion) and ‘Tox’ (toxicity) data to know whether further
optimization of these compounds in the framework of drug
development is appropriate. Therefore, molecules 2a–d as
representative Tubathian ‘mother structures’ were preliminary
screened for their capability to inhibit cytochrome P450 (cyto-
chrome P450 inhibition can cause unanticipated adverse reac-
tions or therapeutic failures), hERG safety (to exclude potential
cardiotoxicity, as inhibition of the hERG might result in fatal
ventricular tachyarrhythmia), microsomal stability in mouse
and human (to measure in vitro intrinsic clearance), and
plasma protein binding in mouse and human (the less bound
a compound is to proteins in blood plasma, the more eﬃci-
ently it can diﬀuse or traverse cell membranes) (Table 3). Appar-
ently, whereas sulfides 2a and 2b were shown to inhibit the
cytochrome P450 enzymes at low micromolar concentrations,
which is harmful for possible drug–drug interactions in vivo,
the sulfones 2c and 2d scored much better in this regard. The
same can be stated for the hERG safety, showing sulfides 2a
and 2b to be inferior as compared to sulfones 2c and 2d. In
the microsomal stability assay and the plasma protein binding
assay, sulfides 2a and 2b seemed diﬃcult to detect, this in
contrast to sulfones 2c and 2d which showed acceptable values
in both assays. In summary, sulfones 2c and 2d clearly demon-
strated a much better preliminary ADME/Tox profile than
sulfides 2a and 2b and might thus be considered as potential
lead compounds for further elaboration in future research.
Additionally, a preliminary ADME/Tox screening of com-
pounds 3i–m concerning cytochrome P450 inhibition and
microsomal stability was conducted (Table 4). From the cyto-
chrome P450 inhibition data, it can be concluded that com-
pounds 3j, 3l and 3m display the best profile, with compound
3m showing no P450 inhibition at all. The microsomal stabi-
lity assays reveal that six-membered sulfoxides 3i and 3j and
five-membered sulfones 3l and 3m have an improved stability
over six-membered sulfones 2c, 2d and 3k. In summary, Ta
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further investigation of six-membered sulfoxide 3j and five-
membered sulfones 3l and 3m seems appropriate from an
ADME/Tox point of view.
In a final assay, the genotoxicity of six-membered sulfone
2c and five-membered sulfone 3l as representative examples
was evaluated, bearing in mind the known potential mutageni-
city associated with hydroxamic acids.14,15 The Ames fluctu-
ation test toward four strains of Salmonella typhimurium (TA98,
TA100, TA1535 and TA1537), with and without metabolic acti-
vation by using rat liver S9 fraction, revealed that both com-
pounds were only mutagenic toward strain TA1537, with and
without S9, starting at a concentration of 50 µM (for more
details, see ESI†). No mutagenicity was detected toward the
other strains.
Conclusions
Thirteen novel Tubathian analogs were synthesized and,
together with four previously developed analogs, evaluated in
depth as HDAC6 inhibitors. The nine para-substituted com-
pounds showed the best HDAC6 IC50-values and proved to be
selective inhibitors in cells. A detailed study of five selected
representatives revealed that these Tubathian analogs preferen-
tially inhibit HDAC6, although also a moderate aﬃnity for
class IIa HDACs (especially HDAC7 and 9) should be recog-
nized. ADME/Tox evaluation demonstrated that sulfones 2c
and 2d display a better preliminary ADME/Tox profile than the
corresponding sulfides 2a and 2b and pointed to six-mem-
bered sulfoxide 3j and five-membered sulfones 3l and 3m as
promising chemical entities. Therefore, further research
should be focused on these oxidized analogs as valuable lead
structures in the pursuit of novel selective HDAC6 inhibitors.
Experimental section
Chemistry. General methods
1H NMR, 13C NMR and 19F NMR spectra were recorded at 400,
100.6 or 376.5 MHz (Bruker Avance III) with CDCl3 or [D6]
DMSO as the solvent and tetramethylsilane as the internal
standard. Mass spectra were obtained with a mass spectro-
meter Agilent 1100, 70 eV. IR spectra were measured with a
Spectrum One FT-IR spectrophotometer. High resolution elec-
tron spray (ES) mass spectra were obtained with an Agilent
Technologies 6210 series time-of-flight instrument. Melting
points of crystalline compounds were measured with a Kofler
Bench, type WME Heizbank of Wagner & Munz. The purity of
all tested compounds was assessed by 1H NMR analysis and/or
HPLC analysis, confirming a purity of ≥95%.
Representative procedure for the synthesis of sulfides 6a–f
To a solution of phenyl hydrazine hydrochloride 4a (12 mmol)
and 4,5-dihydro-3(2H)-thiophenone 5b (12 mmol) in methanol
(50 mL), was added Bi(NO3)3·5H2O (2.4 mmol). After being
stirred for 3.5 h under reflux, the reaction mixture was poured
into water (100 mL), and bismuth nitrate was removed through
filtration over celite. The crude product was extracted with
ethyl acetate (100 mL), washed with saturated NaHCO3
(100 mL), brine (100 mL) and dried over anhydrous MgSO4. Fil-
tration of the drying agent and removal of the solvent in vacuo
aﬀorded the crude cyclic thioether 6c, which was purified by
means of column chromatography (EtOAc/PE 1/5) to provide
pure 2,3-dihydrothieno[3,2-b]indole 6c (3.7 mmol, 31%). The
synthesis of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 6a and
6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene 6b has already
been described previously.9 7-Bromo-2,3-dihydrothieno[3,2-b]
indole 6f was not easily purified because it contained the
corresponding sulfoxide as a side product and was therefore
used as an intermediate for further transformation.
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene 6c. (reaction
time 22 h) 1H NMR (400 MHz, CDCl3): δ 3.00–3.02 (m, 4H),
3.80 (s, 2H), 7.16 (d, J = 8.5 Hz, 1H), 7.23 (d × d, J = 8.5, 1.9 Hz,
1H), 7.57 (d, J = 1.9 Hz, 1H), 7.83 (bs, 1H). 13C NMR
(100.6 MHz, CDCl3): δ 22.5, 25.2, 25.6, 106.7, 111.9, 112.8,
120.3, 124.4, 128.7, 133.1, 134.6. MS (70 eV): m/z (%) = 268/70
([M + 1]+, 58). HRMS (ESI) m/z for C11H11BrNS [M + H]
+ calcd
269.9770, found 269.9769. Yellow powder. Recrystallisation
from EtOH, yield 43%. Mp = 169.5 °C.
Table 4 Preliminary ADME/Tox screening of compounds 3i–m
Compound CYP1A2 (IC50 µM) CYP2C9 (IC50 µM) CYP2C19 (IC50 µM) CYP2D6 (IC50 µM) CYP3A4 (IC50 µM)
3i >50 36.9 15.4 39.8 8.5
3j >50 >50 >50 >50 28.8
3k >50 14.9 30.3 14.1 8.2
3l >50 >50 16.3 >50 >50
3m >50 >50 >50 >50 >50
Compound Mouse MS (µl min−1 mg−1) Mouse MS t1/2 (min) Human MS (µl min−1 mg−1) Human MS t1/2 (min)
3i <2.1 >328 <2.3 >313
3j 8.8 79.1 <2.1 >340
3k 8.2 53.2 13.0 7.6
3l 7.8 89.0 <2.1 >335
3m 10.1 68.9 2.8 247.5
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2,3-Dihydrothieno[3,2-b]indole 6d. 1H NMR (400 MHz,
CDCl3): δ 3.20 and 3.83 (2 × t, J = 7.9 Hz, 2 × 2H), 7.07–7.15 (m,
2H), 7.28–7.31 (m, 1H), 7.36–7.38 (m, 1H), 7.97 (bs, 1H). 13C
NMR (100.6 MHz, CDCl3): δ 28.4, 37.6, 111.6, 113.1, 118.7,
120.0, 121.4, 123.1, 137.1, 140.5. MS (70 eV): m/z (%) = 174 ([M
− 1]−, 100). HRMS (ESI) m/z for C10H10NS [M + H]+ calcd
176.0529, found 176.0526. Brown-orange powder. Column
chromatography Rf (SiO2) = 0.23, EtOAc/PE (1/5), yield 31%.
Mp = 144.0 °C.
7-Fluoro-2,3-dihydrothieno[3,2-b]indole 6e. 1H NMR
(400 MHz, CDCl3): δ 3.18 and 3.81 (2 × t, J = 7.9 Hz, 2 × 2H),
6.86 (t × d, J = 9.0, 2.5 Hz, 1H), 7.02 (d × d, J = 9.4, 2.5 Hz, 1H),
7.18 (d × d, J = 9.0, 4.3 Hz, 1H), 7.95 (bs, 1H). 13C NMR
(100.6 MHz, CDCl3): δ 28.4, 37.6, 103.8 (d, J = 24.3 Hz), 109.5
(d, J = 26.3 Hz), 112.1 (d, J = 9.7 Hz), 113.2 (d, J = 4.4 Hz), 123.2
(d, J = 10.5 Hz), 136.9, 139.3, 157.9 (d, J = 234.9 Hz). 19F NMR
(376.5 MHz, CDCl3): δ (−123.90)–(−123.84) (m). MS (70 eV):
m/z (%) = 192 ([M − 1]−, 100). HRMS (ESI) m/z for C10H7FNS
[M − H]−, calcd 192.0289, found 192.0291. Brown-orange
powder. Column chromatography Rf (SiO2) = 0.20, EtOAc/PE
(1/4), yield 30%. Mp = 133.5 °C.
Representative procedure for the synthesis of sulfoxides 7a–c
To a solution of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 6a
(5 mmol) in tetrahydrofuran (50 mL) was added boron trifluor-
ide diethyl etherate (20 mmol) at −20 °C under nitrogen
atmosphere. Then m-chloroperbenzoic acid was added
(5 mmol) at −20 °C and the mixture was stirred at −20 °C for
2 h. After two hours the reaction mixture was poured into a
saturated solution of NaHCO3 (100 mL) and subsequently
extracted with ethyl acetate (100 mL). The organic phase was
washed with water (2 × 50 mL), brine (50 mL) and dried over
anhydrous MgSO4. Filtration of the drying agent and removal
of the solvent in vacuo aﬀorded the crude cyclic sulfoxide 7a,
which was purified by recrystallization from EtOH to provide
pure 1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 7a
(4.15 mmol, 83%).
1,2,4,9-Tetrahydro-3-thia-9-azafluorene-3-oxide 7a. 1H NMR
(400 MHz, d6-DMSO): δ 3.03–3.34 (m, 4H), 3.93 and 4.21 (2 × d,
J = 15.1 Hz, 2 × 1H), 6.98 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 7.5 Hz,
1H), 7.30 (d, J = 7.5 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 11.10 (bs,
1H). 13C NMR (100.6 MHz, d6-DMSO): δ 17.7, 44.5, 45.1, 98.9,
111.3, 117.7, 119.1, 121.5, 127.8, 132.3, 136.1. MS (70 eV): m/z
(%) = 206 ([M + 1]+, 90). HRMS (ESI) m/z for C11H12NOS [M +
H]+ calcd 206.0634, found 206.0638. Beige powder. Recrystalli-
zation from EtOH, yield 83%. Mp > 260.0 °C.
6-Fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 7b. 1H
NMR (400 MHz, d6-DMSO): δ 3.02–3.33 (m, 4H), 3.93 and 4.16
(2 × d, J = 15.2 Hz, 2 × 1H), 6.89 (t × d, J = 9.0, 2.6 Hz, 1H), 7.22
(d × d, J = 9.9, 2.6 Hz, 1H), 7.29 (d × d, J = 9.0, 4.5 Hz, 1H),
11.14 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 17.5, 44.2,
44.8, 99.4 (d, J = 4.4 Hz), 102.8 (d, J = 23.6 Hz), 109.3 (d, J =
25.9 Hz), 112.2 (d, J = 9.7 Hz), 128.2 (d, J = 10.0 Hz), 132.7,
134.5, 157.3 (d, J = 231.4 Hz). 19F NMR (376.5 MHz, d6-DMSO):
δ (−125.11)–(−125.05) (m). MS (70 eV): m/z (%) = 224 ([M + 1]+,
100). HRMS (ESI) m/z for C11H11FNOS [M + H]
+ calcd 224.0540,
found 224.0548. Yellow powder. Recrystallization from EtOH,
yield 68%. Mp = 242.0 °C.
7-Bromo-2,3-dihydrothieno[3,2-b]indole-1-oxide 7c. 1H NMR
(400 MHz, d6-DMSO): δ 3.15–3.22, 3.28–3.33, 3.59–3.67 and
3.96–4.03 (4 × m, 4 × 1H), 7.33 (d × d, J = 8.6, 1.9 Hz, 1H), 7.43
(d, J = 8.6 Hz, 1H), 7.83 (d, J = 1.9 Hz, 1H), 12.07 (bs, 1H). 13C
NMR (100.6 MHz, d6-DMSO): δ 24.0, 59.0, 113.9, 115.0, 120.8,
120.9, 124.5, 125.3, 140.1, 153.4. MS (70 eV): m/z (%) 270/2 ([M
+ 1]+, 100). HRMS (ESI) m/z for C10H9BrNOS [M + H]
+ calcd
269.9583, found 269.9593. Black powder. Recrystallization
from EtOH, yield 41%. Mp = 191.0 °C.
Representative procedure for the synthesis of sulfones 8a–e
To a solution of 6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluor-
ene 6c (5 mmol) in tetrahydrofuran (50 mL) was added m-
chloroperbenzoic acid in tetrahydrofuran (15 mmol) at 0 °C.
The mixture was stirred at room temperature for 2 h. The
solvent was removed in vacuo and the residue was dissolved in
ethyl acetate (100 mL). The solution was washed with saturated
aqueous sodium sulfite (30 mL), water (30 mL), brine (2 ×
30 mL), and dried over anhydrous MgSO4. Filtration of the
drying agent and removal of the solvent in vacuo aﬀorded the
crude cyclic sulfone 8c, which was purified by recrystallization
from EtOH to provide pure 6-bromo-1,2,4,9-tetrahydro-3-thia-9-
azafluorene-3,3-dioxide 8c (3.05 mmol, 61%). The synthesis of
1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8a and
6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8b
has been described previously.9
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide
8c. 1H NMR (400 MHz, d6-DMSO): δ 3.27 and 3.48 (2 × t, J =
6.1 Hz, 2 × 2H), 4.44 (s, 2H), 7.20 (d × d, J = 8.6, 1.5 Hz, 1H),
7.30 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 11.36 (bs, 1H).
13C NMR (100.6 MHz, d6-DMSO): δ 23.1, 47.1, 48.6, 101.9,
111.9, 113.4, 120.3, 124.3, 129.1, 132.4, 135.2. MS (70 eV): m/z
(%) 322/4 (M+ + 23, 55). HRMS (ESI) m/z for C11H10BrNO2S [M
− H]− calcd 297.9543, found 297.9541. Brown powder. Re-
crystallization from EtOH, yield 61%. Mp = 215.0 °C.
2,3-Dihydrothieno[3,2-b]indole-1,1-dioxide 8d. 1H NMR
(400 MHz, d6-DMSO): δ 3.44 and 3.90 (2 × t, J = 6.6 Hz, 2 × 2H),
7.17–7.21 (m, 1H), 7.24–7.28 (m, 1H), 7.48–7.50 (m, 1H),
7.54–7.56 (m, 1H), 12.00 (bs, 1H). 13C NMR (100.6 MHz, d6-
DMSO): δ 21.4, 57.6, 113.3, 116.1, 118.4, 119.4, 121.9, 123.7,
140.8, 147.7. MS (70 eV): m/z (%) = 208 ([M + 1]+, 30), 225 [M +
NH4
+], 100). HRMS (ESI) m/z for C10H10NO2S [M + H]
+ calcd
208.0427, found 208.0429. Beige powder. Recrystallization
from EtOH, yield 52%. Mp = 260.0 °C.
7-Fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 8e. 1H
NMR (400 MHz, d6-DMSO): δ 3.44 and 3.89 (2 × t, J = 6.6 Hz,
2 × 2H), 7.12 (t × d, J = 9.1, 2.5 Hz, 1H), 7.33 (d × d, J = 9.3, 2.5
Hz, 1H), 7.51 (d × d, J = 9.1, 4.5 Hz, 1H), 12.10 (bs, 1H). 13C
NMR (100.6 MHz, d6-DMSO): δ 21.5, 57.6, 103.8 (d, J =
25.1 Hz), 111.7 (d, J = 25.7 Hz), 114.6 (d, J = 9.8 Hz), 116.2 (d,
J = 4.4 Hz, Cquat,arom), 119.6 (d, J = 11.3 Hz), 137.4, 149.3, 158.3
(d, J = 235.3 Hz). 19F NMR (376.5 MHz, d6-DMSO): δ (−121.35)–
(−121.29) (m). MS (70 eV): m/z (%) = 243 ([M + NH4+], 100).
HRMS (ESI) m/z for C10H9FNO2S [M + H]
+ calcd 226.0333,
Organic & Biomolecular Chemistry Paper
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found 226.0334. Pink powder. Recrystallization from EtOH,
yield 70%. Mp > 260.0 °C.
Representative procedure for the synthesis of 6-phenyl-1,2,4,9-
tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8f
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8c
(2 mmol) was dissolved in toluene (15 mL), and to this solu-
tion an aqueous solution of sodium carbonate (7 mL, 2 M)
and a solution of phenylboronic acid (4 mmol) in ethanol
(7 mL) were added. This mixture was then flushed with nitro-
gen gas for 10 minutes before tetrakis(triphenylphosphine)-
palladium(0) (0.08 mmol) was added, and the reaction mixture
was heated under reflux for 8 hour. The reaction mixture was
then poured into brine (20 mL) and extracted with EtOAc (3 ×
20 mL). The combined organic fraction was washed with brine
(3 × 15 mL), dried (MgSO4), filtered and evaporated under
vacuum. Purification through recrystallization from EtOH
yielded 6-phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 8f (1.2 mmol, 60%) as a light brown powder.
6-Phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide
8f. 1H NMR (400 MHz, d6-DMSO): δ 3.29 and 3.50 (2 × t, J =
6.2 Hz, 2 × 2H), 4.51 (s, 2H), 7.30 (t, J = 7.4 Hz, 1H), 7.39–7.43
(m, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.68 (d, J = 7.4 Hz, 2H), 7.74 (s,
1H), 11.21 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 23.2,
47.2, 48.9, 102.5, 111.8, 116.1, 121.2, 126.8, 127.1, 127.9, 129.2,
131.4, 131.9, 136.2, 142.1. MS (70 eV): m/z (%) 298 ([M + 1]+,
40). HRMS (ESI) m/z for C17H16NO2S [M + H]
+ calcd 298.0896,
found 298.0902. Light brown powder. Recrystallization from
EtOH, yield 60%. Mp = 237.0 °C.
Representative procedure for the synthesis of
N-methoxycarbonylbenzyl-1,2,4,9-tetrahydro-3-thia-9-
azafluorenes 10a–m
1,2,4,9-Tetrahydro-3-thia-9-azafluorene 6a (6 mmol) and sodium
hydride (60 wt% in mineral oil, 6 mmol) were placed under nitro-
gen and dissolved in DMF (10 mL). After stirring for 30 minutes,
methyl 3-(bromomethyl)benzoate 9 (6 mmol) and potassium
iodide (0.06 mmol) were added. The mixture was heated to 80 °C
for 2 h, after which it was quenched with water (30 mL), followed
by addition of ethyl acetate (30 mL). The aqueous layer was
extracted with ethyl acetate (2 × 10 mL) and the combined
organic layers were washed with water (2 × 20 mL) and brine
(15 mL), dried (MgSO4) and concentrated in vacuo. Purification
by means of column chromatography (EtOAc/PE 1/10, Rf =
0.18) aﬀorded pure N-(3-methoxycarbonylbenzyl)-1,2,4,9-tetra-
hydro-3-thia-9-azafluorene 10a (2.46 mmol, 41%).
N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-aza-
fluorene 10a. 1H NMR (400 MHz, CDCl3): δ 2.92 and 3.04 (2 ×
t, J = 5.8 Hz, 2 × 2H), 3.93 (s, 3H), 3.95 (s, 2H), 5.33 (s, 2H),
7.03–7.05 (m, 1H), 7.13–7.20 (m, 2H), 7.24–7.26 (m, 1H), 7.33
(t, J = 7.7 Hz, 1H), 7.52–7.55 (m, 1H), 7.90–7.95 (m, 2H). 13C
NMR (100.6 MHz, CDCl3): δ 23.1, 24.1, 25.9, 46.0, 52.3, 107.3,
108.9, 117.7, 119.5, 121.7, 126.8, 127.4, 128.7, 129.1, 130.5,
130.6, 134.5, 135.7, 138.2, 166.8. MS (70 eV): m/z (%) = 338 ([M
+ 1]+, 90). HRMS (ESI) m/z for C20H20NO2S [M + H]
+ calcd
338.1209, found 338.1219. White-yellow powder. Column
chromatography Rf (SiO2) = 0.18, EtOAc/PE (1/10), yield 41%.
Mp = 115.0 °C.
N-(3-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-
9-azafluorene 10b. 1H NMR (400 MHz, CDCl3): δ 2.89 and 3.00
(2 × t, J = 5.7 Hz, 2 × 2H), 3.85 (s, 2H), 3.90 (s, 3H), 5.27 (s, 2H),
6.87 (t × d, J = 9.1, 2.5 Hz, 1H), 6.99–7.01 (m, 1H), 7.08–7.15
(m, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.84 (s, 1H), 7.90–7.93 (m, 1H).
13C NMR (100.6 MHz, CDCl3): δ 22.9, 24.2, 25.8, 46.2, 52.3,
103.0 (d, J = 23.6 Hz), 107.4 (d, J = 4.4 Hz), 109.5 (d, J = 9.6 Hz),
109.7 (d, J = 26.0 Hz), 127.1 (d, J = 9.7 Hz), 127.3, 128.8, 129.2,
130.4, 130.8, 132.2, 136.3, 137.9, 157.9 (d, J = 235.0 Hz), 166.7.
19F NMR (376.5 MHz, CDCl3): δ (−134.64)–(−124.52) (m). MS
(70 eV): m/z (%) = 356 ([M + 1]+, 100). HRMS (ESI) m/z for
C20H19FNO2S [M + H]
+ calcd 356.1115, found 356.1131. White-
yellow powder. Column chromatography Rf (SiO2) = 0.16,
EtOAc/PE (1/10), yield 50%. Mp = 97.0 °C.
N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-aza-
fluorene-3,3-dioxide 10c. 1H NMR (400 MHz, d6-DMSO): δ 3.21
and 3.51 (2 × t, J = 6.2 Hz, 2 × 2H), 3.82 (s, 3H), 4.51 (s, 2H),
5.53 (s, 2H), 7.06–7.10 (m, 1H), 7.14–7.18 (m, 1H), 7.22–7.25
(m, 1H), 7.45–7.52 (m, 3H), 7.78 (s, 1H), 7.85 (d, J = 7.9 Hz,
1H). 13C NMR (100.6 MHz, d6-DMSO): δ 22.4, 45.9, 46.7, 48.4,
52.7, 102.8, 110.3, 118.3, 120.0, 122.5, 126.6, 127.7, 128.6,
129.8, 130.5, 131.5, 131.6, 137.1, 139.3, 166.4. MS (70 eV): m/z
(%) = 370 ([M + 1]+, 7), 387 ([M + NH4
+], 100). HRMS (ESI) m/z
for C20H20NO4S [M + H]
+, calcd 370.1108, found 370.1111.
Yellow powder. Column chromatography Rf (SiO2) = 0.26,
EtOAc/PE (4/5), yield 21%. Mp = 200.0 °C.
N-(3-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 10d. 1H NMR (400 MHz, d6-
DMSO): δ 3.21 and 3.50 (2 × t, J = 6.1 Hz, 2 × 2H), 3.83 (s, 3H),
4.48 (s, 2H), 5.54 (s, 2H), 7.01 (t × d, J = 9.2, 2.5 Hz, 1H), 7.22
(d, J = 7.9 Hz, 1H), 7.33 (d × d, J = 9.3, 2.5 Hz, 1H), 7.47 (t, J =
7,9 Hz, 1H), 7.51 (d × d, J = 9.2, 4.3 Hz, 1H), 7.77 (s, 1H), 7.86
(d, J = 7.9 Hz, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 22.5,
46.1, 46.6, 48.3, 52.7, 103.1 (d, J = 4.6 Hz), 103.5 (d, J =
24.0 Hz), 110.4 (d, J = 25.9 Hz), 111.5 (d, J = 9.6 Hz), 126.9 (d, J =
10.3 Hz), 127.7, 128.7, 129.8, 130.5, 131.6, 133.5, 133.8, 139.1,
157.7 (d, J = 233.0 Hz), 166.4. 19F NMR (376.5 MHz, d6-DMSO):
δ (−124.05)–(−123.99) (m). MS (70 eV): m/z (%) = 405 ([M +
NH4
+], 100). HRMS (ESI) m/z for C20H19FNO4S [M + H]
+ calcd
388.1013, found 388.1019. Beige powder. Recrystallization
from EtOH, yield 67%. Mp = 214.0 °C.
N-(3-Methoxycarbonylbenzyl)-6-phenyl-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 10e. 1H NMR (400 MHz, d6-
DMSO): δ 3.24 and 3.52 (2 × t, J = 5.9 Hz, 2 × 2H), 3.83 (s, 3H),
4.57 (s, 2H), 5.57 (s, 2H), 7.26 (d, J = 7.7 Hz, 1H), 7.32 (t, J =
7.3 Hz, 1H), 7.44–7.50 (m, 4H), 7.58 (d, J = 8.6 Hz, 1H), 7.70 (d,
J = 7.3 Hz, 2H), 7.81–7.83 (m, 2H), 7.87 (d, J = 7.7 Hz, 1H). 13C
NMR (100.6 MHz, d6-DMSO): δ 22.5, 46.1, 46.7, 48.5, 52.7,
103.4, 110.7, 116.6, 121.7, 126.9, 127.2, 127.7, 128.6, 129.3,
129.8, 130.5, 131.6, 132.3, 132.6, 136.7, 139.3, 141.8, 166.4. MS
(70 eV): m/z (%) 446 ([M + 1]+, 80). HRMS (ESI) m/z for
C26H27N2O4S [M + NH4]
+ calcd 463.1686, found 463.1694.
Light brown powder. Recrystallization from EtOH, yield 60%.
Mp = 201.0 °C.
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N-(3-Methoxycarbonylbenzyl)-2,3-dihydrothieno[3,2-b]indole-
1,1-dioxide 10f. 1H-NMR (400 MHz, d6-DMSO): δ 3.44 (t, J =
6.5 Hz, 2H), 3.84 (s, 3H), 3.95 (t, J = 6.5 Hz, 2H), 5.57 (s, 2H),
7.23–7.32 (m, 2H), 7.42–7.45 (m, 1H), 7.49–7.53 (m, 1H),
7.59–7.62 (m, 2H), 7.88–7.91 (m, 2H). 13C-NMR (100.6 MHz,
d6-DMSO): δ 21.0, 46.9, 52.7, 57.4, 112.3, 116.2, 118.8, 119.3,
122.5, 124.0, 128.2, 129.0, 129.9, 130.6, 132.3, 137.9, 141.0,
148.5, 166.4. MS (70 eV): m/z (%) = 373 ([M + NH4
+], 100).
HRMS (ESI) m/z for C19H18NO4S [M + H]
+ calcd 356.0951,
found 356.0958. White powder. Recrystallization from EtOH,
yield 72%. Mp = 210.5 °C.
N-(3-Methoxycarbonylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-
b]indole-1,1-dioxide 10g. 1H NMR (400 MHz, d6-DMSO): δ 3.44
(t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.95 (t, J = 6.5 Hz, 2H), 5.57 (s,
2H), 7.18 (t × d, J = 9.2, 2.5 Hz, 1H), 7.39–7.44 (m, 2H),
7.49–7.53 (m, 1H), 7.63 (d × d, J = 9.2, 4.3 Hz, 1H), 7.89–7.91
(m, 2H). 13C NMR (100.6 MHz, d6-DMSO): δ 21.1, 47.1, 52.7,
57.3, 104.3 (d, J = 25.2 Hz), 112.1 (d, J = 26.0 Hz), 113.7 (d, J =
9.9 Hz), 116.2 (d, J = 4.4 Hz), 119.5 (d, J = 11.2 Hz), 128.2,
129.1, 130.0, 130.6, 132.3, 137.6, 137.7, 150.1, 158.7 (d, J =
236.9 Hz), 166.4. 19F NMR (376.5 MHz, d6-DMSO): δ (−120.57)–
(−120.50) (m). MS (70 eV): m/z (%) = 391 ([M + NH4+], 100).
HRMS (ESI) m/z for C19H17FNO4S [M + H]
+ calcd 374.0857,
found 374.0857. White powder. Recrystallization from EtOH,
yield 60%. Mp = 222.0 °C.
N-(3-Methoxycarbonylbenzyl)-7-bromo-2,3-dihydrothieno
[3,2-b]indole-1-oxide 10h. 1H NMR (400 MHz, CDCl3):
δ 3.01–3.07 (m, 1H), 3.45–3.51 (m, 1H), 3.61–3.69 (m, 1H),
3.91–4.00 (m, 1H), 3.91 (s, 3H), 5.29 and 5.35 (2 × d, J = 16.4
Hz, 2 × 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H),
7.34 (d × d, J = 8.8, 1.8 Hz, 1H), 7.40 (t, J = 7.7 Hz, 1H), 7.90 (s,
1H), 7.96 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 7.7 Hz, 1H). 13C NMR
(100.6 MHz, CDCl3): δ 23.8, 48.9, 52.4, 58.3, 112.0, 115.5,
120.9, 122.1, 124.3, 126.3, 127.8, 129.5, 129.6, 130.9, 131.2,
135.8, 140.1, 152.4, 166.4. MS (70 eV): m/z (%) 418/20 ([M + 1]+,
100). HRMS (ESI) m/z for C19H17BrNO3S [M + H]
+ calcd
418.0107, found 418.0125. Brown powder. Column chromato-
graphy Rf (SiO2) = 0.23, acetone/PE (1/1), yield 54%. Mp =
187.5 °C.
N-(4-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-aza-
fluorene-3-oxide 10i. 1H NMR (400 MHz, d6-DMSO):
δ 2.98–3.16 (m, 3H), 3.28–3.38 (m, 1H), 3.82 (s, 3H), 4.03 and
4.23 (2 × d, J = 15.4 Hz, 2 × 1H), 5.53 (s, 2H), 7.05–7.14 (m, 2H),
7.17 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.0 Hz, 1H), 7.52 (d, J =
7.5 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H). 13C NMR (100.6 MHz, d6-
DMSO): δ 16.6, 44.0, 44.8, 45.9, 52.6, 99.8, 110.1, 118.1, 119.8,
122.0, 127.1, 127.6, 129.1, 130.1, 133.2, 136.7, 144.2, 166.4. MS
(70 eV): m/z (%) = 354 ([M + 1]+, 70). HRMS (ESI) m/z for
C20H20NO3S [M + H]
+ calcd 354.1158, found 354.1153. Brown
powder. Recrystallization from EtOH, yield 47%. Mp = 78.0 °C.
N-(4-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-
9-azafluorene-3-oxide 10j. 1H NMR (400 MHz, d6-DMSO): δ
2.97–3.14 (3H, m), 3.32–3.36 (m, 1H), 3.82 (s, 3H), 4.02 and
4.18 (2 × d, J = 15.3 Hz, 2 × 1H), 5.53 (s, 2H), 6.96 (t × d, J = 9.0,
2.5 Hz, 1H), 7.16 (d, J = 8.3 Hz, 2H), 7.33 (d × d, J = 9.7, 2.5 Hz,
1H), 7.45 (d × d, J = 9.0, 4.3 Hz, 1H), 7.90 (d, J = 8.3 Hz, 2H).
13C NMR (100.6 MHz, d6-DMSO): δ 16.5, 43.7, 44.6, 46.1, 52.6,
100.1 (d, J = 4.4 Hz), 103.3 (d, J = 23.8 Hz), 109.8 (d, J =
26.0 Hz), 111.2 (d, J = 9.6 Hz), 127.1, 128.0 (d, J = 10.2 Hz),
129.1, 130.1, 133.4, 135.3, 143.9, 157.7 (d, J = 232.6 Hz), 166.4.
19F NMR (376.5 MHz, d6-DMSO): δ (−124.41)–(−124.34) (m).
MS (70 eV): m/z (%) = 372 ([M + 1]+, 77). HRMS (ESI) m/z for
C20H19FNO3S [M + H]
+ calcd 372.1064, found 372.1065. Brown
powder. Recrystallization from EtOH, yield 42%. Mp =
135.5 °C.
N-(4-Methoxycarbonylbenzyl)-6-bromo-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 10k. 1H NMR (400 MHz,
CDCl3): δ 3.25–3.28 and 3.30–3.33 (2 × m, 2 × 2H), 3.90 (s, 3H),
4.37 (s, 2H), 5.32 (s, 2H), 7.01 (d, J = 8.5 Hz, 2H), 7.09 (d, J =
8.7 Hz, 1H), 7.30 (d × d, J = 8.7, 1.8 Hz, 1H), 7.57 (d, J = 1.8 Hz,
1H), 7.97 (d, J = 8.5 Hz, 2H). 13C NMR (100.6 MHz, CDCl3):
δ 22.2, 46.7, 47.2, 48.7, 52.3, 102.2, 111.0, 113.8, 120.4, 125.8,
125.9, 128.0, 130.0, 130.5, 131.4, 135.9, 141.3, 166.4. MS
(70 eV): m/z (%) 448/50 ([M + 1]+, 70). HRMS (ESI) m/z for
C20H22BrN2O4S [M + NH4]
+ calcd 465.0478, found 465.0473.
Light brown powder. Column chromatography Rf (SiO2) = 0.25,
EtOAc/PE (1/1), yield 80%. Mp = 191.0 °C.
N-(4-Methoxycarbonylbenzyl)-2,3-dihydrothieno[3,2-b]indole-
1,1-dioxide 10l. 1H NMR (400 MHz, d6-DMSO): δ 3.44 (t, J =
6.5 Hz, 2H), 3.83 (s, 3H), 3.95 (t, J = 6.5 Hz, 2H), 5.57 (s, 2H),
7.23–7.31 (m, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.55–7.62 (m, 2H),
7.94 (d, J = 8.4 Hz, 2H). 13C NMR (100.6 MHz, d6-DMSO):
δ 20.9, 47.0, 52.6, 57.4, 112.2, 116.3, 118.8, 119.3, 122.5, 124.0,
127.8, 129.5, 130.2, 141.0, 142.5, 148.6, 166.3. MS (70 eV): m/z
(%) = 356 ([M + 1]+, 41), 373 ([M + NH4
+], 100). HRMS (ESI) m/z
for C19H18NO4S [M + H]
+ calcd 356.0951, found 356.0954.
White powder. Recrystallization from EtOH, yield 60%. Mp =
226.5 °C.
N-(4-Methoxycarbonylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-
b]indole-1,1-dioxide 10m. 1H NMR (400 MHz, d6-DMSO):
δ 3.44 (t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.95 (t, J = 6.5 Hz, 2H),
5.57 (s, 2H), 7.16 (t × d, J = 9.2, 2.5 Hz, 1H), 7.34 (d, J = 8.3 Hz,
2H), 7.41 (d × d, J = 9.1, 2.5 Hz, 1H), 7.59 (d × d, J = 9.2, 4.3 Hz,
1H), 7.94 (d, J = 8.3 Hz, 2H). 13C NMR (100.6 MHz, d6-DMSO):
δ 21.0, 47.2, 52.7, 57.3, 104.3 (d, J = 25.1 Hz), 112.1 (d, J =
25.8 Hz), 113.7 (d, J = 9.9 Hz), 116.3 (d, J = 4.5 Hz), 119.5 (d, J =
11.3 Hz), 127.8, 129.6, 130.2, 137.6, 142.2, 150.1, 158.7 (d, J =
236.9 Hz), 166.3. 19F NMR (376.5 MHz, d6-DMSO): δ (−120.57)–
(−120.51) (m). MS (70 eV): m/z (%) = 391 ([M + NH4+], 100).
HRMS (ESI) m/z for C19H17FNO4S [M + H]
+ calcd 374.0857,
found 374.0852. White powder. Recrystallization from EtOH,
yield 80%. Mp = 243.0 °C.
Representative procedure for the synthesis of hydroxamic
acids 3a–m
N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-aza-
fluorene 10a (1 mmol) was dissolved in THF (10 mL), and to
this solution was added hydroxylamine (100 mmol) and sub-
sequently potassium hydroxide in methanol (4 M, 50 mmol).
The resulting mixture was stirred for an additional 10 minutes
at room temperature, before it was poured into a saturated
aqueous solution of NaHCO3 (10 mL). This aqueous solution
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem.
Pu
bl
ish
ed
 o
n 
05
 Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
by
 K
U
 L
eu
ve
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
03
/0
2/
20
16
 1
5:
07
:4
6.
 
View Article Online
was extracted two times with ethyl acetate, after which the
combined organic fractions were washed with water (10 mL)
and a saturated brine solution (10 mL), dried (MgSO4), filtered
and evaporated. Purification through recrystallization from
EtOH yielded N-(3-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-
3-thia-9-azafluorene 3a (0.57 mmol, 57%) as a white-yellow
powder. Note: the mixture was stirred at reflux temperature for
the synthesis of hydroxamic acids 3d, 3g and 3m.
N-(3-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-
azafluorene 3a. 1H NMR (400 MHz, d6-DMSO): δ 2.90 and
3.00 (2 × t, J = 5.5 Hz, 2 × 2H), 3.84 (s, 2H), 5.42 (s, 2H),
7.01–7.05 (m, 1H), 7.07–7.11 (m, 2H), 7.36 (t, J = 7.7 Hz, 1H),
7.42 (d, J = 7.7 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.54 (s, 1H),
7.58 (d, J = 7.7, 1H), 9.00 (bs, 1H), 11.19 (bs, 1H). 13C NMR
(100.6 MHz, d6-DMSO): δ 22.7, 24.0, 25.6, 45.7, 106.8, 109.9,
118.0, 119.4, 121.5, 125.8, 125.9, 126.7, 129.2, 129.5, 133.7,
135.4, 135.7, 139.3, 164.6. MS (70 eV): m/z (%) = 339 ([M + 1]+,
100). HRMS (ESI) m/z for C19H19N2O2S [M + H]
+ calcd
339.1162, found 339.1159. White-yellow powder. Crystalliza-
tion from EtOH, yield 57%. Mp = 124.5 °C.
N-(3-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-
thia-9-azafluorene 3b. 1H NMR (400 MHz, d6-DMSO): δ 2.89
and 2.99 (2 × t, J = 5.4 Hz, 2 × 2H), 3.81 (s, 2H), 5.42 (s, 2H),
6.92 (t × d, J = 9.1, 2.5 Hz, 1H), 7.07 (d, J = 7.7 Hz, 1H), 7.26
(d × d, J = 9.7, 2.5 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.44 (d × d, J =
9.1, 4.4 Hz, 1H), 7.51 (s, 1H), 7.59 (d, J = 7.7 Hz, 1H), 9.04 (bs,
1H), 11.14 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 22.6,
24.2, 25.5, 45.9, 103.1 (d, J = 23.4 Hz), 107.1 (d, J = 4.4 Hz),
109.3 (d, J = 25.8 Hz), 110.9 (d, J = 9.8 Hz), 125.7, 125.9, 127.0
(d, J = 10.1 Hz), 129.2, 129.4, 132.4, 133.7, 137.5, 139.0, 157.5
(d, J = 232.0 Hz), 164.5. 19F NMR (376.5 MHz, d6-DMSO):
δ (−124.92)–(−124.86) (m). MS (70 eV): m/z (%) = 357 ([M + 1]+,
100). HRMS (ESI) m/z for C19H18FN2O2S [M + H]
+ calcd
357.1068, found 357.1062. Yellow powder. Crystallization from
diethyl ether, yield 63%. Mp = 190.0 °C.
N-(3-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-
azafluorene-3,3-dioxide 3c. 1H NMR (400 MHz, d6-DMSO):
δ 3.24 and 3.51 (2 × t, J = 6.0 Hz, 2 × 2H), 4.50 (s, 2H), 5.47 (s,
2H), 7.06–7.11 (m, 2H), 7.14–7.18 (m, 1H), 7.37 (t, J = 7.9 Hz,
1H), 7.48–7.51 (m, 2H), 7.59–7.61 (m, 2H), 9.04 (bs, 1H), 11.22
(bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 22.4, 46.2, 46.7,
48.4, 102.7, 110.4, 118.2, 120.0, 122.4, 126.0, 126.1, 126.6,
129.3, 129.5, 131.5, 133.8, 137.1, 138.9, 164.5. MS (70 eV): m/z
(%) = 371 ([M + 1]+, 95). HRMS (ESI) m/z for C19H19N2O4S [M +
H]+ calcd 371.1060, found 371.1066. Yellow powder. Crystalli-
zation from diethyl ether, yield 32%. Mp = 229.5 °C.
N-(3-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 3d. 1H NMR (400 MHz,
d6-DMSO): δ 3.23 and 3.50 (2 × t, J = 5.9 Hz, 2 × 2H), 4.48 (s,
2H), 5.47 (s, 2H), 7.00 (t × d, J = 9.1, 2.5 Hz, 1H), 7.08 (d, J =
7.5 Hz, 1H), 7.32 (d × d, J = 9.7, 2.5 Hz, 1H), 7.34–7.38 (m, 1H),
7.50 (d × d, J = 9.1, 4.3 Hz, 1H), 7.58 (s, 1H), 7.61 (d, J = 7.5 Hz,
1H), 9.05 (bs, 1H), 11.21 (bs, 1H). 13C NMR (100.6 MHz, d6-
DMSO): δ 22.5, 46.4, 46.6, 48.3, 102.9 (d, J = 4.6 Hz), 103.4 (d,
J = 24.0 Hz), 110.3 (d, J = 26.1 Hz), 111.5 (d, J = 9.5 Hz), 125.9,
126.1, 126.9 (d, J = 10.2 Hz), 129.2, 129.4, 133.5, 133.7, 133.8,
138.6, 157.7 (d, J = 232.9 Hz), 164.3. 19F NMR (376.5 MHz, d6-
DMSO): δ (−124.15)–(−124.09) (m). MS (70 eV): m/z (%) = 389
([M + 1]+, 100). HRMS (ESI) m/z for C19H18FN2O4S [M + H]
+
calcd 389.0966, found 389.0967. White powder. Crystallization
from EtOH, yield 5%. Mp = 237.0 °C.
N-(3-Hydroxycarbamoylbenzyl)-6-phenyl-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 3e. 1H NMR (400 MHz, d6-
DMSO): δ 3.25 and 3.52 (2 × t, J = 5.8 Hz, 2 × 2H), 4.57 (s, 2H),
5.49 (s, 2H), 7.10 (d, J = 7.4 Hz, 1H), 7.30–7.36 (m, 2H),
7.44–7.48 (m, 3H), 7.57 (d, J = 8.6 Hz, 1H), 7.61–7.63 (m, 2H),
7.70 (d, J = 7.2 Hz, 2H), 7.81 (s, 1H) 9.02 (bs, 1H), 11.17 (bs,
1H). 13C NMR (100.6 MHz, d6-DMSO): δ 22.5, 46.4, 46.7, 48.5,
103.2, 110.8, 116.5, 121.6, 125.7, 126.0, 126.9, 127.1, 127.2,
129.1, 129.2, 129.3, 132.3, 132.5, 134.2, 136.7, 138.6, 141.8,
164.0. MS (70 eV): m/z (%) 447 ([M + 1]+, 85). HRMS (ESI) m/z
for C25H23N2O4S [M + H]
+ calcd 447.1373, found 447.1361.
White powder. Crystallization from CH2Cl2, yield 63%. Mp =
214.0 °C.
N-(3-Hydroxycarbamoylbenzyl)-2,3-dihydrothieno[3,2-b]indole-
1,1-dioxide 3f. 1H NMR (400 MHz, d6-DMSO): δ 3.47 and 3.96
(2 × t, J = 6.5 Hz, 2 × 2H), 5.50 (s, 2H), 7.22–7.34 (m, 3H), 7.43
(t, J = 7.9 Hz, 1H), 7.58–7.61 (m, 2H), 7.65–7.66 (m, 2H), 9.04
(bs, 1H), 11.24 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO):
δ 21.0, 47.1, 57.4, 112.3, 116.1, 118.7, 119.3, 122.5, 123.9,
126.3, 126.6, 129.4, 130.3, 133.8, 137.4, 141.0, 148.5, 164.3. MS
(70 eV): m/z (%) = 357 ([M + 1]+, 100). HRMS (ESI) m/z for
C18H17N2O4S [M + H]
+ calcd 357.0904, found 357.0907. White
powder. Crystallisation from ethanol, yield 25%. Mp =
236.5 °C.
N-(3-Hydroxycarbamoylbenzyl)-7-fluoro-2,3-dihydrothieno
[3,2-b]indole-1,1-dioxide 3g. 1H NMR (400 MHz, d6-DMSO):
δ 3.47 and 3.96 (2 × t, J = 6.5 Hz, 2 × 2H), 5.51 (s, 2H), 7.17 (t ×
d, J = 9.2, 2.5 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.38–7.45 (m,
2H), 7.61 (d × d, J = 9.2, 4.3 Hz, 1H), 7.65–7.67 (m, 2H), 9.04
(bs, 1H), 11.23 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO):
δ 21.1, 47.3, 57.3, 104.2 (d, J = 25.4 Hz), 112.0 (d, J = 25.8 Hz),
113.8 (d, J = 9.7 Hz), 116.1 (d, J = 4.4 Hz), 119.5 (d, J = 11.2 Hz),
126.3, 126.7, 129.5, 130.3, 133.9, 137.2, 137.6, 150.1, 158.7 (d,
J = 236.6 Hz), 164.3. 19F NMR (376.5 MHz, d6-DMSO):
δ (−120.64)–(−120.58) (m). MS (70 eV): m/z (%) = 375 ([M + 1]+,
87). HRMS (ESI) m/z for C18H16FN2O4S [M + H]
+ calcd
375.0809, found 375.0810. White powder. Crystallisation from
diethyl ether, yield 40%. Mp > 260.0 °C.
N-(3-Hydroxycarbamoylbenzyl)-7-bromo-2,3-dihydrothieno
[3,2-b]indole-1-oxide 3h. 1H NMR (400 MHz, d6-DMSO):
δ 3.24–3.31 (m, 1H), 3.36–3.43 (m, 1H), 3.57–3.64 (m, 1H),
4.00–4.07 (m, 1H), 5.51 and 5.57 (2 × d, J = 16.3 Hz, 2 × 1H),
7.31 (d, J = 7.9 Hz, 1H), 7.38 (d × d, J = 8.8, 1.9 Hz, 1H), 7.42 (t,
J = 7.9 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.64–7.66 (m, 2H), 7.90
(d, J = 1.9 Hz, 1H), 9.04 (bs, 1H), 11.23 (bs, 1H). 13C NMR
(100.6 MHz, d6-DMSO): δ 23.9, 48.5, 58.5, 114.1, 114.6, 120.4,
121.2, 124.4, 125.5, 126.3, 126.6, 129.4, 130.2, 133.9, 137.4,
140.2, 154.6, 166.3. MS (70 eV): m/z (%) 419/21 ([M + 1]+, 100).
HRMS (ESI) m/z for C18H16BrN2O3S [M + H]
+ calcd 419.0060,
found 419.0056. White powder. Recrystallization from CH2Cl2,
yield 70%. Mp = 218.5 °C.
Paper Organic & Biomolecular Chemistry
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N-(4-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-
azafluorene-3-oxide 3i. 1H NMR (400 MHz, d6-DMSO):
δ 3.02–3.16 (m, 3H), 3.32–3.38 (m, 1H), 4.03 and 4.22 (2 × d, J =
15.2 Hz, 2 × 1H), 5.48 (s, 2H), 7.04–7.15 (m, 4H), 7.44 (d, J =
8.1 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H),
9.00 (bs, 1H), 11.14 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO):
δ 16.6, 43.9, 44.8, 45.9, 99.7, 110.1, 118.1, 119.8, 122.0, 126.8,
127.6, 127.7, 132.3, 133.2, 136.7, 141.7, 164.4. MS (70 eV): m/z
(%) = 355 ([M + 1]+, 100). HRMS (ESI) m/z for C19H19N2O3S [M
+ H]+ calcd 355.1111, found 355.1112. White powder. Crystalli-
sation from EtOH, yield 13%. Mp = 258.5 °C.
N-(4-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3-oxide 3j. 1H NMR (400 MHz, d6-DMSO):
δ 3.01–3.15 (m, 3H), 3.28–3.38 (m, 1H), 4.02 and 4.17 (2 × d, J =
15.6 Hz, 2 × 1H), 5.44 (s, 2H), 6.95 (t × d, J = 9.0, 2.5 Hz, 1H),
7.09 (d, J = 8.2 Hz, 2H), 7.32 (d × d, J = 9.7, 2.5 Hz, 1H), 7.45 (d
× d, J = 9.0, 4.3 Hz, 1H), 7.67 (d, J = 8.2 Hz, 2H), 9.00 (bs, 1H),
11.15 (bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 16.5, 43.7,
44.6, 46.0, 100.0 (d, J = 4.3 Hz), 103.3 (d, J = 23.7 Hz), 109.8 (d,
J = 26.1 Hz), 111.2 (d, J = 9.7 Hz), 126.8, 127.8, 128.0 (d, J = 10.0
Hz), 132.4, 133.3, 135.3, 141.5, 157.7 (d, J = 231.9 Hz), 164.4. 19F
NMR (376.5 MHz, d6-DMSO): δ (−124.45)–(−124.39) (m). MS (70
eV): m/z (%) = 373 ([M + 1]+, 100). HRMS (ESI) m/z for
C19H18FN2O3S [M + H]
+ calcd 373.1017, found 373.1014. White
powder. Crystallisation from EtOH, yield 28%. Mp = 244.5 °C.
N-(4-Hydroxycarbamoylbenzyl)-6-bromo-1,2,4,9-tetrahydro-3-
thia-9-azafluorene-3,3-dioxide 3k. 1H NMR (400 MHz, d6-
DMSO): δ 3.22 and 3.51 (2 × t, J = 5.9 Hz, 2 × 2H), 4.51 (s, 2H),
5.50 (s, 2H), 7.07 (d, J = 8.2 Hz, 2H), 7.27 (d × d, J = 8.7, 1.7 Hz,
1H), 7.47 (d, J = 8.7 Hz, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.75 (d, J =
1.7 Hz, 1H), 9.01 (bs, 1H), 11.16 (bs, 1H). 13C NMR
(100.6 MHz, d6-DMSO): δ 22.4, 46.2, 46.5, 48.2, 102.7, 112.5,
112.7, 120.8, 124.8, 126.8, 127.8, 128.3, 132.5, 133.3, 135.8,
141.2, 164.3. MS (70 eV): m/z (%) 449/51 ([M + 1]+, 5). HRMS
(ESI) m/z for C19H18BrN2O4S [M + H]
+ calcd 449.0165, found
449.0148. White powder. Crystallisation from CH2Cl2, yield
70%. Mp = 230.0 °C.
N-(4-Hydroxycarbamoylbenzyl)-2,3-dihydrothieno[3,2-b]indole-
1,1-dioxide 3l. 1H NMR (400 MHz, d6-DMSO): δ 3.46 and 3.96
(2 × t, J = 6,3 Hz, 2 × 2H), 5.51 (2H, s), 7.22–7.30 (m, 4H),
7.56–7.61 (m, 2H), 7.71 (d, J = 8.2 Hz, 2H), 9.03 (bs, 1H), 11.17
(bs, 1H). 13C NMR (100.6 MHz, d6-DMSO): δ 20.9, 47.0, 57.4,
112.3, 116.1, 118.7, 119.3, 122.5, 123.9, 127.5, 127.9, 132.7,
140.1, 140.9, 148.5, 164.2. MS (70 eV): m/z (%) = 357 ([M + 1]+,
33), 374 ([M + NH4
+], 100). HRMS (ESI) m/z for C18H17N2O4S
[M + H]+ calcd 357.0904, found 357.0900. White powder. Crys-
tallisation from EtOH, yield 25%. Mp = 198.0 °C.
N-(4-Hydroxycarbamoylbenzyl)-7-fluoro-2,3-dihydrothieno
[3,2-b]indole-1,1-dioxide 3m. 1H NMR (400 MHz, d6-DMSO):
δ 3.47 and 3.96 (2 × t, J = 6.5 Hz, 2 × 2H), 5.51 (s, 2H), 7.16 (t × d,
J = 9.2, 2.5 Hz, 1H), 7.29 (d, J = 8.2 Hz, 2H), 7.40 (d × d, J = 9.1,
2.5 Hz, 1H), 7.60 (d × d, J = 9.2, 4.3 Hz, 1H), 7.72 (d, J = 8.2 Hz,
2H), 9.03 (bs, 1H), 11.19 (bs, 1H). 13C NMR (100.6 MHz, d6-
DMSO): δ 21.0, 47.2, 57.3, 104.3 (d, J = 25.3 Hz), 112.0 (d, J =
26.2 Hz), 113.7 (d, J = 9.8 Hz), 116.2 (d, J = 5.3 Hz), 119.5 (d, J =
11.1 Hz), 127.5, 127.9, 132.8, 137.6, 139.9, 150.1, 158.7 (d, J =
235.5 Hz), 164.2. 19F NMR (376.5 MHz, d6-DMSO): δ (−120.60)–
(−120.54) (m). MS (70 eV): m/z (%) = 392 ([M + NH4+], 100).
HRMS (ESI) m/z for C18H19FN3O4S [M + NH4
+] calcd 392.1075,
found 392.1075. White powder. Crystallisation from diethyl
ether, yield 5%. Mp = 240.5 °C.
Docking studies (performed at the Centre for Industrial
Biotechnology and Biocatalysis)
All manipulations were performed with the molecular model-
ling program YASARA and the YASARA/WHATIF twinset,16 and
the figure was created with PyMol v1.3.17 The HDAC6
sequence was obtained from the UniProt database (http://
www.uniprot.org, UniProt entry Q9UBN7). To increase the
accuracy of the model, the sequence was limited to the major
functional domain of HDAC6 (Gly482–Gly800). Possible tem-
plates were identified by running 3 PSI-BLAST iterations to
extract a position specific scoring matrix (PSSM) from
UniRef90, and then searching the PDB for a match. To aid the
alignment of the HDAC6 sequence and templates, and the
modelling of the loops, a secondary structure prediction was
performed, followed by multiple sequence alignments. All
side chains were ionised or kept neutral according to their
predicted pKa values. Initial models were created from
diﬀerent templates (pdb entry 2VQW, 2VQQ and 3C10), each
with several alignment variations and up to hundred confor-
mations tried per loop. After the side-chains had been built,
optimised and fine-tuned, all newly modelled parts were sub-
jected to a combined steepest descent and simulated anneal-
ing minimisation, i.e. the backbone atoms of aligned residues
were kept fixed to preserve the folding, followed by a full
unrestrained simulated annealing minimisation for the entire
model. The final model was obtained as a hybrid model of the
best parts of the initial models, and checked once more for
anomalies like incorrect configurations or colliding side
chains. Furthermore, it was structurally aligned with known
HDAC crystal structures to check if the chelating residues and
the zinc atom were arranged correctly. The HDAC inhibitor
structures were created with YASARA Structure and energy
minimised with the AMBER03 force field.18 The grid box used
for docking had a dimension of 25 × 25 × 25 angstrom, and
comprised the entire catalytic cavity including the zinc ion
and the outer surface of the active site entrance. Docking was
performed with AutoDock VINA19 and default parameters.
Ligands were allowed to freely rotate during docking. The first
conformer from the cluster that has its zinc binding group in
the vicinity of the zinc ion, was selected as the binding mode
for analysis.
Enzyme inhibition assay (performed by Eurofins Cerep
Panlabs)
In vitro determination of IC50-values by using human recombi-
nant HDAC1-11 and fluorogenic HDAC substrate.20 For more
details, see ESI.†
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Western blots (performed at the Laboratory of Neurobiology
and Vesalius Research Center, VIB)
Values represent the normalized ratio acetyl α-tubulin/
α-tubulin and acetyl histone 3/histone 4 against Tubastatin A
(Tub A) in an established neuronal cell line (Neuro-2a cells:
ATCC N° CCL-131).
Cell culture
Mouse neuroblastoma (Neuro-2a) cells were grown in a
1 : 1 mix of D-MEM (Dulbecco’s Modified Eagle Medium) and
F12 medium supplemented with glutamax (Life Technologies),
100 μg per ml streptomycin, 100 U per ml penicillin (Life
Technologies), 10% fetal calf serum (Greiner Bio-one), 1%
non-essential amino acids (Life Technologies) and 1.6%
NaHCO3 (Life Technologies) at 37 °C and 7.5% CO2. To split
the cells, cells were washed with Versene (Life Technologies)
and dissociated with 0.05% Trypsine-EDTA (Life Techno-
logies). The Neuro-2a cells were treated overnight at 37 °C with
dosages ranging from 10 nM up to 1 μM of either Tubastatin A
(Asclepia, Destelbergen, Belgium) or the candidate HDAC6
inhibitors, and the eﬀect on the acetylation level of α-tubulin
is determined by using western blot. For more details, see
ESI.†
Western blot
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis, treated cells were collected using the
EpiQuik Total Histone Extraction Kit (EpiGentek) according to
manufacturer’s instructions. Protein concentrations were
determined using microBCA kit (Thermo Fisher Scientific Inc.,
Pittsburgh, PA, USA) according to manufacturer’s instructions.
Before resolving the samples on a 12% SDS-PAGE gel, samples
containing equal amounts of protein were supplemented with
reducing sample buﬀer (Thermo Scientific) and boiled at
95 °C for 5 min. After electrophoresis, the proteins were trans-
ferred to a polyvinylidene difluoride (PVDF) membrane (Milli-
pore Corp.). The non-specific binding was blocked by
incubation of the membrane in 5% bovine serum albumin
(BSA), diluted in Tris Buﬀered Saline Tween (TBST, 50 mM
TRIS, 150 mM NaCl, 0.1% Tween-20 (Applichem, Darmstadt,
Germany) overnight followed by incubation with primary anti-
bodies during one hour. The antibodies, diluted in TBS-T,
were directed against α-tubulin (Sigma-Aldrich, T6199, 1/5000,
1h), against acetylated α-tubulin (Sigma-Aldrich, T6793,
1/5000, 1h), against glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH, Life Technologies, AM4300, 1/5000, 1h), against
histone H3 acetyl k9-k14 (Cell Signaling, 9677L, 1/500, 1h) and
against histone 4 (Abcam, ab10158, 1/500, 1h). The secondary
antibodies, coupled to alkaline phosphatase (anti-mouse or
anti-rabbit, Sigma-Aldrich, 1/5000, 1h) were used. Blots were
visualized by adding the ECF substrate (Enhanced Chemical
Fluorescence, GE Healthcare, Uppsala, Sweden) and imaged
with the ImageQuant_LAS 4000. A mild reblotting buﬀer
(Millipore) was applied to strip the blots. ImageQuant TL
version 7.0-software was used to quantify the blots.
Ames fluctuation assay (performed by Eurofins Cerep Panlabs)
Wells that displayed bacteria growth due to the reversion of
the histidine mutation (as judged by the ratio of OD430/
OD570 being greater than 1.0) are counted and recorded as
positive counts. The significance of the positive counts
between the treatment (in the presence of test compound) and
the control (in the absence of test compound) are calculated
using the one-tailed Fisher’s exact test. Three significance
levels are reported as follows: weak positive, if 0.01 ≤ p < 0.05,
denoted as “+”, strong positive, if 0.001 ≤ p < 0.01, denoted as
“++”, very strong positive, if p < 0.001, denoted as “+++”. For
more details, see ESI.†
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